CAS 94367-21-2: Suc-Leu-Leu-Val-Tyr-AMC

Suc-Leu-Leu-Val-Tyr-AMC is a cyclin D2 inhibitor that binds to the proteasome and inhibits its function. It has been shown to be useful for the treatment of cancerous tissues as it inhibits the production of prostaglandin J2, which is involved in the progression of cancer cells. Suc-Leu-Leu-Val-Tyr-AMC has also been shown to have antioxidant properties and can inhibit oxidative injury. This drug may be used to prevent or treat various diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, diabetes mellitus type II, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and septic shock.

Suc-Leu-Leu-Val-Tyr-AMC is a fluorescent substrate for the 20S proteasome, other chymotrypsin-like proteases.

The fluorogenic substrate Suc-LLVY-AMC is used for measuring the chymotrypsin-like activity of the 20S proteasome, in combination with e.g. Bz-VGR-AMC (for assaying its trypsin-like activity) and Z-LLE-AMC (for determining its PGPH activity). Suc-LLVY-AMC is also cleaved by a chymotrypsin-like enzyme from sperm extract of the ascidian Halocynthia roretzi, a strong inhibitor of fertilization. The substrate has also been used to analyze the chymotrypsin-like activity of trypsins as well as chymase from rat mast cells. Furthermore, Suc-LLVY-AMC is a substrate for carboxypeptidase Y, proteinase yscE (kexin), ingensin, as well as for porcine calpain isozymes I and II and for papain.

Suc-Leu-Leu-Val-Tyr-AMC is a peptide that is an activator of ion channels. It can be used to study the effects of ion channel activation on various cells and tissues. Suc-Leu-Leu-Val-Tyr-AMC has also been shown to inhibit ligand binding to some receptors, such as the acetylcholine receptor. This peptide can also be used as a research tool for pharmacology, protein interactions, and antibody production.